Market Recovers as Key Investors Make Moves

Market activity on May 15, 2026, showed resilience with indices recovering despite macroeconomic pressures like a weaker rupee and high crude oil prices. Amidst this environment, significant block trades highlighted changing investor interests. Zerodha's investment in Nazara Technologies and Stellar Wealth Partners' purchase in Sakar Healthcare signal careful investment choices, while ICICI Prudential Mutual Fund's move in Pidilite Industries reinforces backing for a consumer staple firm.

Major Deals Detail Investor Activity

On May 15, 2026, notable activity included: Zerodha Broking bought Rs 93 crore of Nazara Technologies shares (35 lakh shares, 0.94% stake) at Rs 265.85 each. Nazara's stock then jumped 12.76% to Rs 299.95. Stellar Wealth Partners India Fund acquired a 0.87% stake in Sakar Healthcare (1.95 lakh shares for Rs 12.95 crore) at Rs 664.58 each. This news sent Sakar Healthcare's stock up 16.16% to a record closing high of Rs 696.7 on strong volume. Separately, ICICI Prudential Mutual Fund bought 2 lakh shares of Pidilite Industries from the Balvant K Parekh Foundation at Rs 1,460 per share.

Nazara: Zerodha Invests Amid Promoter Activity

Zerodha's Rs 93 crore investment in Nazara Technologies occurs alongside significant activity from promoter entities Mitter Infotech LLP and Axana Estates LLP. These firms shuffled large blocks of shares, selling 1.92 crore shares and buying 1.47 crore shares near Rs 266 each. While the promoter activity appears balanced, it adds caution. Nazara's valuation is complex, with P/E ratios reported from negative to over 140, and more recent figures ranging from 11.5 to 28.63, despite Q4 FY26 profit growth. The stock's one-year return has been negative, around -4% to -12%. The gaming sector also faces regulatory pressures and competition, potentially limiting growth.

Sakar Healthcare: Stellar Wealth Buys In

Stellar Wealth Partners India Fund's investment in Sakar Healthcare fits its strategy of targeting strong businesses with long-term trends. The fund focuses on risk management and capital preservation, using a fee structure with no management fees and performance pay only above an 8% hurdle. Stellar's entry helped push Sakar Healthcare to a record Rs 696.7. Sakar's stock has surged over 90% in the past year. However, its P/E ratio of about 44 is high compared to industry peers, which average around 29.3.

Pidilite: ICICI MF Adds to Stake

ICICI Prudential Mutual Fund's purchase of 2 lakh shares in Pidilite Industries shows ongoing institutional confidence. Pidilite holds a premium valuation with a P/E ratio around 60, suggesting investors anticipate steady, market-leader growth.

Valuation Snapshots and Market Context

Valuations vary across these companies. Sakar Healthcare has a P/E of about 44 and a market cap near Rs 1,479 crore, appearing expensive against pharmaceutical peers averaging a P/E of 30. Nazara Technologies has a complex valuation, but a P/E around 25 might be considered, despite challenges in the gaming sector. Market leader Pidilite Industries trades at a higher P/E of around 60. The broader market showed recovery on May 15, 2026, with Nifty 50 closing at 23,689.60 and Sensex at 75,398.72.

Sector Trends and Risks

Sakar Healthcare operates in the resilient pharmaceutical sector, though its premium valuation requires attention. Nazara Technologies faces ongoing regulatory and competitive pressures in India's gaming and media sector, which could affect growth. Pidilite Industries benefits from stable demand in consumer durables, linked to economic cycles. Meanwhile, broader market risks persist, including a weakening rupee (hitting 95.96/$) and high crude oil prices.

Key Risks for Investors

Key risks exist for these companies. Nazara Technologies faces caution due to promoter share shuffling, valuation uncertainty, and sector regulations. Sakar Healthcare's premium valuation of around 44 (vs. peers averaging 31.2) leaves little room for error if growth slows. Pidilite Industries, at a P/E of about 60, also has future growth largely priced in, making it vulnerable to slowdowns.

Analyst Views and Market Outlook

Analyst views on Nazara Technologies are mixed, with some seeing value and others cautioning on earnings and sector issues. Analyst ratings for Sakar Healthcare were not readily available, but its high valuation implies expectations for strong future results. Pidilite Industries' steady performance typically draws consistent analyst attention to its growth and dividends. The market outlook for May 2026 is cautiously optimistic, with Nifty 50 needing to clear 23,800 for further gains, while support is seen near 23,200.